Journal
NEUROTHERAPEUTICS
Volume 10, Issue 1, Pages 2-18Publisher
SPRINGER
DOI: 10.1007/s13311-012-0163-4
Keywords
Interferon beta; Glatiramer acetate; Multiple sclerosis therapeutics; Review; History
Funding
- National MS Society
- Acorda Therapeutics, Inc.
- Biogen Idec
- Novartis Pharmaceuticals Corp
- Teva Neuroscience, Inc.
- Genzyme
- Sanofi
- Celgene
- NIH
- NMSS Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals
- EMD Serono, Inc
- Novartis
- Pfizer
- Teva Neuroscience
- Actelion
- Sanofi-Aventis
- Acorda
- Questcor
- Roche
- Genentech
- Johnson Johnson
- Revalesio
- Coronado Bioscience, Genzyme, MedImmune
- Bristol-Myers Squibb
Ask authors/readers for more resources
Interferon beta and glatiramer acetate have been mainstays of treatment in relapsingremitting multiple sclerosis for two decades. Remarkable advances in our understanding of immune function and dysfunction as well as increasingly sophisticated clinical trial design have stemmed from efforts to better understand these drugs. In this chapter, we review the history of their development and elaborate on known and theorized mechanisms of action. We describe the pivotal clinical trials that have led to their widespread use. We evaluate the clinical use of the drugs including tolerability, side effects, and efficacy measures. Finally, we look to the future of interferon beta and glatiramer acetate in the context of an ever growing armamentarium of treatments for relapsing remitting multiple sclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available